Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Gayathri Ravi, Susan Bal, Kelly Godby, Smith Giri, Courtney Hebert, Binita Parekh, JoAnn Steele, Jessica Brown, Kathy Langley, Luciano Costa

Blood (2023) 142 (Supplement 1): 6920.

https://doi.org/10.1182/blood-2023-188323

Published: 2023

Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal

Blood (2023) 142 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2023-178735

Published: 2023

Journal Articles

Hospital Associated Disability Among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell Transplant

Kyle Kidwell, Rui Zhu, Susan Bal, Kelly Godby, Gayathri Ravi, Luciano Costa, Sadeep Shrestha, Grant Williams, Smita Bhatia, Smith Giri

Blood (2023) 142 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2023-189205

Published: 2023

Journal Articles

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Tylan Magnusson, Luciano Costa, Smith Giri, Gayathri Ravi, Kelly Godby, Binod Dhakal, Bhagirathbhai Dholaria, Eva Medvedova, Natalie S. Callander, JoAnn Steele, Kathy Langley, Baylie Mullinax, Melissa Sentell, Stephen Horn, Candace Hill, Megan Boullion, Susan Bal

Blood (2023) 142 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2023-187343

Published: 2023

Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 219.

https://doi.org/10.1182/blood-2023-181857

Published: 2023

Journal Articles

Immune Profiling of Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Induction and Autologous Stem Cell Transplantation (ASCT) and Comparison with Achievement of Minimal Residual Disease (MRD) Negativity

Susan Bal, Esther Zumaquero, Gayathri Ravi, Kelly Godby, Smith Giri, Ashley Denslow, Joaquin Bauta Perez, Fen Zhou, Suki Chen, Megan Padilla, Amna Siddiqui, Clare Ubersax, Erin Hornsby, Luciano Costa, Frances E Lund

Blood (2023) 142 (Supplement 1): 4685.

https://doi.org/10.1182/blood-2023-187551

Published: 2023

Journal Articles

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Smith Giri, Smith Giri, Clare Ubersax, Abigail Tucker, Susan Bal, Kelly Godby, Luciano Costa, Smita Bhatia, Grant Williams, Gayathri Ravi, Mayur Narkhede, Donna Murdaugh

Blood (2023) 142 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2023-189872

Published: 2023

Journal Articles

Health Outcome Preferences Among Older Adults with Multiple Myeloma Undergoing Systemic Therapy

Miguel Arias, Clare Ubersax, Abigail Tucker, Susan Bal, Gayathri Ravi, Kelly Godby, Luciano Costa, Grant Williams, Sadeep Shrestha, Smita Bhatia, Smith Giri

Blood (2023) 142 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2023-189623

Published: 2023

Journal Articles

Outcomes of Patients with Newly Diagnosed Multiple Myeloma Experiencing Treatment Failure after Upfront Quadruplet Therapy and Autologous Stem Cell Transplantationgayathri Ravi 1 , Susan Bal 1 , Kelly Godby 1 , Smith Giri 1 , Clare Ubersax 1 , Abigail Tucker 1 , Luciano J Costa 1

Gayathri Ravi, Susan Bal, Kelly Godby, Smith Giri, Clare Ubersax, Abigail Tucker, Luciano Costa

Blood (2023) 142 (Supplement 1): 1989.

https://doi.org/10.1182/blood-2023-188272

Published: 2023

Journal Articles

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Binod Dhakal, Meera Mohan, Ravi Narra, Katie Palen, Aniko Szabo, Tyce Kearl, Gayathri Ravi, Susan Bal, Bryon D. Johnson, Marcelo Pasquini, Anita D'Souza, Parameswaran N. Hari, Luciano Costa

Blood (2023) 142 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2023-181266

Published: 2023

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Journal Articles

Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

Gayathri Ravi, Smith Giri, Susan Bal, Kelly N. Godby, Vishnu V.B. Reddy, Donna Salzman, Omar Alkharabsheh, Scott A. McDaniel, Melissa Sentell, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 8048–8049.

https://doi.org/10.1182/blood-2022-170099

Published: 2022

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Safety, Feasibility, and Efficacy of Upfront Daratumumab-Based Therapy in Blacks with Dysproteinemia

Hyndavi Kandala, Smith Giri, Gayathri Ravi, Kelly N. Godby, Deanna Clark, Clare Ubersax, Luciano J. Costa, Susan Bal

Blood (2022) 140 (Supplement 1): 13198–13199.

https://doi.org/10.1182/blood-2022-170978

Published: 2022

Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7275–7277.

https://doi.org/10.1182/blood-2022-156730

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Luciano J. Costa, Kelly N. Godby, Gayathri Ravi, Smith Giri, Susan Bal

Blood (2022) 140 (Supplement 1): 10084–10085.

https://doi.org/10.1182/blood-2022-165882

Published: 2022

Journal Articles

Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)

Andrew Gahagan, Sunil Rangarajan, Clare Ubersax, Abigail Tucker, Christian Harmon, Monica Sai Pasala, Susan Bal, Kelly N. Godby, Gayathri Ravi, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 10079–10080.

https://doi.org/10.1182/blood-2022-165432

Published: 2022

Journal Articles

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Timothy Martin Schmidt, Rebecca Silbermann, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Natalie Callander, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10077–10078.

https://doi.org/10.1182/blood-2022-164930

Published: 2022

Journal Articles

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Nicole Watts, Courtney Hebert, Clare Ubersax, Deanna Clark, Gayathri Ravi, Susan Bal, Purnima Singh, Kelly N. Godby, Donna Salzman, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2022) 140 (Supplement 1): 5248–5249.

https://doi.org/10.1182/blood-2022-163649

Published: 2022

NARROW

Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hospital Associated Disability Among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell Transplant

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Immune Profiling of Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Induction and Autologous Stem Cell Transplantation (ASCT) and Comparison with Achievement of Minimal Residual Disease (MRD) Negativity

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Health Outcome Preferences Among Older Adults with Multiple Myeloma Undergoing Systemic Therapy

Outcomes of Patients with Newly Diagnosed Multiple Myeloma Experiencing Treatment Failure after Upfront Quadruplet Therapy and Autologous Stem Cell Transplantationgayathri Ravi 1 , Susan Bal 1 , Kelly Godby 1 , Smith Giri 1 , Clare Ubersax 1 , Abigail Tucker 1 , Luciano J Costa 1

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Safety, Feasibility, and Efficacy of Upfront Daratumumab-Based Therapy in Blacks with Dysproteinemia

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only